ME02996B - Indolkarb0niтrili као selekтivni modulatori receptora androgena - Google Patents

Indolkarb0niтrili као selekтivni modulatori receptora androgena

Info

Publication number
ME02996B
ME02996B MEP-2018-16A MEP201816A ME02996B ME 02996 B ME02996 B ME 02996B ME P201816 A MEP201816 A ME P201816A ME 02996 B ME02996 B ME 02996B
Authority
ME
Montenegro
Prior art keywords
androgen receptor
receptor modulators
selective androgen
selective
modulators
Prior art date
Application number
MEP-2018-16A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Philip Stewart Turn8Ull
Rodolfo Cadilla
Original Assignee
Glaxosmithкiine Biologicals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02996(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithкiine Biologicals S A filed Critical Glaxosmithкiine Biologicals S A
Publication of ME02996B publication Critical patent/ME02996B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
MEP-2018-16A 2012-07-17 2013-07-15 Indolkarb0niтrili као selekтivni modulatori receptora androgena ME02996B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04
EP13758975.0A EP2875013B1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators
PCT/IB2013/001530 WO2014013309A1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
ME02996B true ME02996B (me) 2018-10-20

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-16A ME02996B (me) 2012-07-17 2013-07-15 Indolkarb0niтrili као selekтivni modulatori receptora androgena

Country Status (39)

Country Link
US (5) US8957104B2 (cs)
EP (1) EP2875013B1 (cs)
JP (1) JP6106746B2 (cs)
KR (1) KR102127939B1 (cs)
CN (1) CN104619693B (cs)
AR (1) AR091770A1 (cs)
AU (1) AU2013291721B2 (cs)
BR (1) BR112015000940B1 (cs)
CA (1) CA2879104C (cs)
CL (1) CL2015000119A1 (cs)
CO (1) CO7240378A2 (cs)
CR (1) CR20150008A (cs)
CY (1) CY1120064T1 (cs)
DK (1) DK2875013T3 (cs)
DO (1) DOP2015000004A (cs)
EA (1) EA026371B8 (cs)
ES (1) ES2657912T3 (cs)
HK (1) HK1208867A1 (cs)
HR (1) HRP20180061T1 (cs)
HU (1) HUE036238T2 (cs)
IL (1) IL236448A (cs)
IN (1) IN2014KN02993A (cs)
JO (1) JO3384B1 (cs)
LT (1) LT2875013T (cs)
ME (1) ME02996B (cs)
MX (1) MX349943B (cs)
MY (2) MY198512A (cs)
NZ (1) NZ703129A (cs)
PE (1) PE20150371A1 (cs)
PH (1) PH12015500104B1 (cs)
PL (1) PL2875013T3 (cs)
PT (1) PT2875013T (cs)
RS (1) RS56810B1 (cs)
SG (1) SG11201408493WA (cs)
SI (1) SI2875013T1 (cs)
TW (1) TWI574946B (cs)
UY (1) UY34911A (cs)
WO (1) WO2014013309A1 (cs)
ZA (1) ZA201500096B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
ES2657912T3 (es) * 2012-07-17 2018-03-07 Glaxosmithkline Intellectual Property (No. 2) Limited Indolcarbonitrilos como moduladores selectivos de los receptores de andrógenos
WO2015110958A1 (en) 2014-01-21 2015-07-30 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile
EP3206675A4 (en) * 2014-10-16 2018-07-11 GTx, Inc. METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特（成都）生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010041343A (ko) 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 효소의 억제제
ATE265458T1 (de) * 1998-06-19 2004-05-15 Pfizer Prod Inc Pyrrolo(2,3-d)pyrimidin-verbindungen
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
CN100475789C (zh) 2002-05-24 2009-04-08 拜尔农作物科学股份公司 制备烷硫基胺衍生物的方法
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
EP1756109B1 (en) 2004-05-03 2016-07-13 Janssen Pharmaceutica NV Novel indole derivatives as selective androgen receptor modulators (sarms)
CN102091068B (zh) 2004-05-03 2012-09-19 詹森药业有限公司 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
RU2382031C2 (ru) 2004-06-01 2010-02-20 Ф. Хоффманн-Ля Рош Аг 3-амино-1-арилпропилиндолы, применяемые в качестве ингибиторов обратного захвата моноаминов
PT1913000E (pt) * 2005-07-29 2012-02-28 Pfizer Prod Inc Derivados de pirrolo[2,3-d]pirimidina, suas substâncias intermédias e processo de síntese
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
CA2645731A1 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
ES2452343T3 (es) * 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
SI2384326T1 (sl) * 2008-08-20 2014-06-30 Zoetis Llc Pirolo(2,3-d)pirimidinske spojine
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
CN102574860A (zh) * 2009-10-15 2012-07-11 辉瑞大药厂 吡咯并[2,3-d]嘧啶化合物
EP2513114B1 (en) * 2009-12-18 2014-04-02 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
DK2590647T3 (en) 2010-07-07 2018-02-12 Univ Texas Pro-neurogenic compounds
AU2012208837B2 (en) * 2011-01-20 2016-07-28 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
KR102032934B1 (ko) * 2011-12-21 2019-10-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도
ES2657912T3 (es) * 2012-07-17 2018-03-07 Glaxosmithkline Intellectual Property (No. 2) Limited Indolcarbonitrilos como moduladores selectivos de los receptores de andrógenos
WO2015110958A1 (en) * 2014-01-21 2015-07-30 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile

Also Published As

Publication number Publication date
AR091770A1 (es) 2015-02-25
BR112015000940A2 (pt) 2017-06-27
BR112015000940B1 (pt) 2022-05-17
EA026371B1 (ru) 2017-03-31
SG11201408493WA (en) 2015-02-27
EP2875013A1 (en) 2015-05-27
EA201492237A1 (ru) 2015-06-30
KR20150032333A (ko) 2015-03-25
CN104619693A (zh) 2015-05-13
IL236448A0 (en) 2015-02-26
AU2013291721B2 (en) 2016-02-25
DK2875013T3 (en) 2018-01-22
EP2875013B1 (en) 2017-11-29
LT2875013T (lt) 2018-02-26
CN104619693B (zh) 2019-08-13
CL2015000119A1 (es) 2015-04-24
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
US20150080449A1 (en) 2015-03-19
TWI574946B (zh) 2017-03-21
RS56810B1 (sr) 2018-04-30
ZA201500096B (en) 2017-07-26
US20190127326A1 (en) 2019-05-02
US8957104B2 (en) 2015-02-17
AU2013291721A1 (en) 2015-02-26
DOP2015000004A (es) 2015-03-15
KR102127939B1 (ko) 2020-06-29
JP6106746B2 (ja) 2017-04-05
MX2015000825A (es) 2015-07-17
HRP20180061T1 (hr) 2018-02-23
IN2014KN02993A (cs) 2015-05-08
CO7240378A2 (es) 2015-04-17
MX349943B (es) 2017-08-21
US10710963B2 (en) 2020-07-14
EA026371B8 (ru) 2017-06-30
CR20150008A (es) 2015-03-09
HK1208867A1 (en) 2016-03-18
PH12015500104A1 (en) 2015-03-02
SI2875013T1 (en) 2018-03-30
CA2879104C (en) 2020-08-25
US20170073309A1 (en) 2017-03-16
CA2879104A1 (en) 2014-01-23
MY198512A (en) 2023-09-01
UY34911A (es) 2014-02-28
PH12015500104B1 (en) 2015-03-02
US11299457B2 (en) 2022-04-12
HUE036238T2 (hu) 2018-06-28
US20140024694A1 (en) 2014-01-23
IL236448A (en) 2016-10-31
ES2657912T3 (es) 2018-03-07
US20200270210A1 (en) 2020-08-27
PT2875013T (pt) 2018-02-28
PE20150371A1 (es) 2015-03-27
CY1120064T1 (el) 2018-12-12
US9533948B2 (en) 2017-01-03
JP2015522603A (ja) 2015-08-06
JO3384B1 (ar) 2019-03-13
MY173845A (en) 2020-02-24
PL2875013T3 (pl) 2018-06-29
WO2014013309A1 (en) 2014-01-23
US10196353B2 (en) 2019-02-05

Similar Documents

Publication Publication Date Title
HK1211039A1 (en) Engineering -cell receptors
GB201213700D0 (en) Receptor antagnists II
EP2531029A4 (en) SELECTIVE ANDROGEN RECEPTOR MODULATORS
IL251897A0 (en) X-receptor modulators of the liver
HK1208867A1 (en) Indolecarbonitriles as selective androgen receptor modulators
HK1206333A1 (en) Liver receptor modulators
HK1209744A1 (en) Novel selective androgen receptor modulators
EP2825299A4 (en) MIXING SYSTEM
IL231440A0 (en) Selective androgen receptor modulators
GB201223053D0 (en) Receptor
PL2820010T3 (pl) Pochodne benzofurano-2-sulfonamidu jako modulatory receptora chemokinowego